194 related articles for article (PubMed ID: 36313225)
1. Possibility of Multiple Drug-Drug Interactions in Patients Treated with Statins: Analysis of Data from the Japanese Adverse Drug Event Report (JADER) Database and Verification by Animal Experiments.
Negishi A; Oshima S; Mutoh M; Horii N; Inoue N; Numajiri S; Ohshima S; Kobayashi D
Int J Med Sci; 2022; 19(12):1816-1823. PubMed ID: 36313225
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis.
Gosho M
Fundam Clin Pharmacol; 2019 Jun; 33(3):339-346. PubMed ID: 30575126
[TBL] [Abstract][Full Text] [Related]
3. Polypharmacy in elderly patients in Japan: Analysis of Japanese real-world databases.
Mabuchi T; Hosomi K; Yokoyama S; Takada M
J Clin Pharm Ther; 2020 Oct; 45(5):991-996. PubMed ID: 31986233
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
5. Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Sato K; Mano T; Iwata A; Toda T
J Alzheimers Dis; 2021; 82(3):1333-1344. PubMed ID: 34151816
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan
.
Hashiguchi M; Hakamata J; Shimizu M; Maruyama J; Shiga T; Mochizuki M
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):310-320. PubMed ID: 29701171
[TBL] [Abstract][Full Text] [Related]
7. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Adverse Drug Reaction Risk in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Chisaki Y; Aoji S; Yano Y
Biol Pharm Bull; 2017; 40(6):824-829. PubMed ID: 28566626
[TBL] [Abstract][Full Text] [Related]
9. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan.
Sunaga T; Ryo Y
Am J Cardiol; 2022 Mar; 166():127-130. PubMed ID: 34963512
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Appendicitis Cases in the Japanese Adverse Drug Event Report (JADER) Database.
Kyotani Y; Zhao J; Nakahira K; Yoshizumi M
Biol Pharm Bull; 2023; 46(5):655-660. PubMed ID: 37121692
[TBL] [Abstract][Full Text] [Related]
11. Polypharmacy in three different spontaneous adverse drug event databases.
Mabuchi T; Hosomi K; Yokoyama S; Takada M
Int J Clin Pharmacol Ther; 2020 Nov; 58(11):601-607. PubMed ID: 32729825
[TBL] [Abstract][Full Text] [Related]
12. Quality evaluation of the Japanese Adverse Drug Event Report database (JADER).
Tsuchiya M; Obara T; Sakai T; Nomura K; Takamura C; Mano N
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):173-181. PubMed ID: 31823506
[TBL] [Abstract][Full Text] [Related]
13. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
14. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
Catapano AL
Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
[TBL] [Abstract][Full Text] [Related]
15. Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study.
Gosho M
J Clin Pharmacol; 2018 Oct; 58(10):1324-1331. PubMed ID: 29762878
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis.
Fujiwara M; Kawasaki Y; Yamada H
PLoS One; 2016; 11(4):e0154425. PubMed ID: 27119382
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database.
Noda A; Sakai T; Obara T; Miyazaki M; Tsuchiya M; Oyanagi G; Murai Y; Mano N
BMC Pharmacol Toxicol; 2020 May; 21(1):36. PubMed ID: 32448369
[TBL] [Abstract][Full Text] [Related]
18. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
19. Association of non-steroidal anti-inflammatory drug use with encephalopathy development: An analysis using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases.
Kawada K; Ishida T; Yoshioka T; Fukuda H; Hayashi T; Goda M; Ishizawa K
Pharmazie; 2024 Jun; 79(6):118-123. PubMed ID: 38877682
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases.
Lavallee M; Yu T; Evans L; Van Hemelrijck M; Bosco C; Golozar A; Asiimwe A
BMC Med Inform Decis Mak; 2022 Feb; 22(1):31. PubMed ID: 35115001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
